Bias in studies of venous thromboembolism in relation to the use of new formulations of oral contraceptives

Contraception

Volumn 55, Issue 3, 1997, Pages 189-190

  Weiss, N S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; GESTODENE; LEVONORGESTREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

CASE CONTROL STUDY; DRUG MARKETING; HUMAN; LETTER; ORAL DRUG ADMINISTRATION; THROMBOEMBOLISM;

EID: 0030888008     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(97)00002-4     Document Type: Letter

References (6)

1. MA Lewis LAJ Heinemann KD MacRae R Bruppacher WO Spitzer The increased risk of venous thromboembolism and use of third generation progestagens: role of bias in observational research Contraception 54 1996 5 13
2. NR Poulter CL Chang TMM Farley O Meirik MG Marmot World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study Lancet 346 1995 1575 1582
3. W Kuhnz S Beier Comparative progestational and androgenic activity of norgestimate and levonorgestrel in the rat Contraception 49 1994 255 263
4. W Kuhnz H Blode M Mahler Systematic availability of levonorgestrel after single dose oral administration of a norgestimate-containing combination oral contraceptive to 12 young women Contraception 49 1994 255 263
5. JL McGuire A Phillips DW Hahn EL Tolman S Flor ME Kafrissen Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites Am J Obstet Gynecol 163 1990 2127 2131
6. SL Corson Norgestimate Clin Obstet Gynecol 38 1995 841 848